|
|
 |
|
Viewing report
|
|
|
|
U.S. Biopharmaceutical Market - Trends, Forecast, Competition & Strategic Analysis (2009 - 2016)
Markets and Markets, Dec 2010, Pages: 378
The U.S. biopharmaceuticals market is expected to increase to $144 billion by 2016. The growth is expected as a result of the launch of new products, approval of new indications for existing therapies and drugs, and increase in population aged 65 years and above. From 2009 to 2016 the U.S. market revenues are forecast to grow at a compound annual growth rate (CAGR) of 11.2%.
This research report analyzes the U.S. biopharmaceuticals market and its growth factors, with special emphasis on the top companies in the field and their product pipeline. While it looks at the overall market size and presents forecast till 2016, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has led to the metamorphosis of the pharmaceutical industry, resulting in the subset industry of biopharmaceuticals. The big players in the pharma industry, including Pfizer, Merck, and Novartis, have been the first few to reap the benefits of investing in biotechnology through both organic as well as inorganic growth mechanisms.
Market forecasts include the biopharmaceuticals currently in the market as well as those projected to enter the market by the end of the forecast period in 2016. Market challenges, drivers, and restraints have also been identified and assessed. Selected late stage pipeline analysis is also included.
This report analyzes the biopharmaceutical industry’s products, features, companies, market size and potential, and patent portfolios. The impact of the Medicare and Medicaid policies and individual plan behaviors on the biopharmaceutical industry is also discussed.
Market Overview
This section discusses the market definition of U.S. biopharmaceutical market. This section also discusses the way market is segmented and the methodology as well as the assumptions considered for forecasting the revenues for the all the individual product/drug class segments.
Market segmentation
This research service covers biopharmaceuticals and their impact on the U.S. healthcare market.
Products included in this study by their market segmentation:
- Gene and Cell therapies, including “Antisense Therapies”
- Cytokines
- PEH: Proteins, Enzymes, and Hormones
- Monoclonal Antibodies
- Vaccines
- Others: Blood and Allergenic components and others.
Products not included:
- Biosurgical products like tissue grafts and sealants
- Biologics used for diagnostic purposes
- Bionanotechnology drugs
Analysis Insights:
This section discusses the current trends and focus of the U.S. biopharmaceutical market and the challenges faced by the industry. Other sections include market analysis, patent analysis and competitive landscape.
Company Profiles:
This section provides the company profiles of major companies participating in the U.S. biopharmaceutical market. Company profiles include a brief overview of the company, primary business, strategies followed and developments
|
|
|
|
